Clinical course of different long-acting insulin therapies—glargine U100, U300, degludec, and insulin degludec/insulin aspart—among Japanese patients with type 2 diabetes: a multicenter retrospective observational study (JDDM65 study)-Reference-Cited by-同舟云学术

Clinical course of different long-acting insulin therapies—glargine U100, U300, degludec, and insulin degludec/insulin aspart—among Japanese patients with type 2 diabetes: a multicenter retrospective observational study (JDDM65 study)

Published:2022 Issue:7 Volume:69 Page:763-771
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Iwamoto Masahiro¹,Nakanishi Shuhei²,Iwamoto Hideyuki²,Kaneto Hideaki²,Maegawa Hiroshi³,

Affiliation:

1. Iwamoto Clinic, Kagawa, Japan

2. Division of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Okayama, Japan

3. Department of Medicine, Division of Diabetology, Endocrinology, and Nephrology, Shiga University of Medical Science, Shiga, Japan

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.jstage.jst.go.jp/article/endocrj/69/7/69_EJ21-0647/_pdf

Reference26 articles.

1. 1 Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, et al. (2018) IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 138: 271–281.

2. 2 Nanditha A, Ma RCW, Ramachandran A, Snehalatha C, Chan JCN, et al. (2016) Diabetes in Asia and the pacific: implications for the global epidemic. Diabetes Care 39: 472–485.

3. 3 Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, et al. (2007) Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 357: 1716–1730.

4. 4 American Diabetes Association (2020) 9. Pharmacological approach to glycemic treatment. Diabetes Care 43 (Suppl 1): S98–S110.

5. 5 Haahr H, Fita EG, Heise T (2017) A review of insulin degludec/insulin aspart: pharmacokinetic and pharmacodynamic properties and their implications in clinical use. Clin Pharmacokinet 56: 339–354.